Traders should monitor upcoming clinical updates in mid-2026 (monotherapy) and second half of 2026 (combination) for confirmation of clinical activity; positive data could drive significant upside in this low-market-cap biotech. Synergy with pembrolizumab may enhance partnership or licensing potential.
Price Chart
Executive Summary
Pyxis Oncology announced preclinical data showing that a mouse analog of its drug MICVO (maMICVO) demonstrated dose-dependent tumor growth inhibition and synergistic anti-tumor activity when combined with anti-PD-1 therapy in an immunotherapy-refractory head and neck cancer model. These findings support ongoing clinical trials of MICVO as monotherapy and in combination with pembrolizumab for recurrent/metastatic HNSCC.
Key Facts
- Preclinical data show maMICVO monotherapy inhibited tumor outgrowth in a syngeneic HNSCC model in a dose-dependent manner, with 6 mg/kg showing strongest effect
- Combination of maMICVO and anti-mouse PD-1 showed synergistic anti-tumor activity in an immunotherapy-refractory model, with greater tumor control than either agent alone
- maMICVO modulated the tumor immune environment by reducing regulatory T cells (Tregs), increasing CD8+ T cell-to-Treg ratio, and enhancing progenitor exhausted T cells responsive to anti-PD-1
- Data to be presented at AACR 2026; supports ongoing Phase 1/2 trials of MICVO alone and with pembrolizumab in R/M HNSCC
- MICVO has Fast Track Designation from FDA for R/M HNSCC previously treated with platinum and anti-PD-(L)1 therapy
Financial Impact
Non-material at this stage; preclinical data support clinical development but no revenue or earnings impact expected in near term
Risk Factors
- Preclinical results may not translate to clinical efficacy in humans
- Clinical trial delays or safety issues could derail development
- Low market cap ($107M) implies high risk; dependent on successful trial outcomes
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3276488 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | 8-K | $3.38 $3.34 | ▼ −1.18% | ▼ −0.09% | $2.14 (−36.69%) |
Sep 8, 2026 24d ago | 8-K | $3.89 $3.33 | ▼ −14.40% | ▼ −13.28% | $2.14 (−44.99%) |
Aug 28, 2026 5w ago | EFFECT | $3.23 $3.89 | ▼ −20.43% | ▼ −20.32% | $2.14 (+33.75%) |
Aug 13, 2026 7w ago | 8-K | $3.01 $3.12 | ▲ +3.65% | ▲ +5.62% | $2.14 (−28.90%) |
Jul 2, 2026 13w ago | 8-K | $2.63 $2.64 | ▲ +0.38% | ▼ −0.55% | $2.14 (−18.63%) |
Jun 30, 2026 13w ago | 144 | $2.85 $3.07 | ▲ +7.72% | ▲ +7.46% | $2.14 (−24.91%) |
Jun 30, 2026 13w ago | Press Release | $3.01 $2.46 | ▼ −18.27% | ▼ −18.88% | $2.14 (−28.90%) |
May 14, 2026 20w ago | 8-K | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.14 (−3.17%) |
May 14, 2026 20w ago | Press Release | $2.21 $1.94 | ▼ −12.22% | ▼ −11.50% | $2.14 (−3.17%) |
Apr 30, 2026 22w ago | DEFA14A | $1.70 $2.26 | ▲ +32.94% | ▲ +31.21% | $2.14 (+25.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access